Prevalence of CKD-MBD in pre-dialysis patients using biochemical markers in Enugu, South-East Nigeria by Okoye, JU et al.
Prevalence of  CKD-MBD in pre-dialysis patients using biochemical markers 
in Enugu, South-East Nigeria
Julius U. Okoye, Ejikeme B. Arodiwe, Ifeoma I. Ulasi, Chinwuba K. Ijoma, Obinna D. Onodugo.
Renal Unit, University of  Nigeria Teaching Hospital, Ituku/Ozalla, Enugu, Nigeria.
Abstract
Background: As kidney function declines, there is a progressive deterioration in mineral homeostasis with disruption of  
normal serum and tissue concentration of  phosphorus and calcium, and changes in circulating levels of  hormones-parathy-
roid hormone (PTH), calcitriol (1,25(OH)2 D), and Fibroblast growth factor-23 (FGF-23). 
Objective: This study was aimed at determining the prevalence of  markers of  CKD-MBD in pre-dialysis patients. 
Methods: We evaluated consecutively 168 subjects made up of  85 CKD patients and 83 healthy controls, who were attend-
ing the renal clinics and medical outpatient of  University of  Nigeria Teaching Hospital, Enugu. GFR was estimated and 
serum calcium, phosphorus, alkaline phosphatase, PTH, and 25(OH) D levels assayed. 
Results: The prevalence of  various mineral bone disease abnormalities were 70% hyper-phosphatemia, 85% hyper-par-
athyroidism, and 100% low levels of  25 (OH) D among the patients. Estimated GFR correlated negatively with both serum 
phosphorus, and PTH. Age of  the patients ranged from18-76 years with a male to female ratio of  1.7:1. Chronic Glo-
merulonephritis (CGN), hypertension and diabetes mellitus caused CKD in 75% of  the patients. There was no significant 
decrease in serum calcium levels of  patients compared to controls. The patients did not have pathologically raised alkaline 
phosphatase, although their mean level was significantly higher than that of  the control group.
Conclusion: Low 25 (OH) D levels (insufficiency/deficiency), hyperparathyroidism, and hyper-phosphatemia were the 
obvious markers of  CKD-MBD in our pre-dialysis patients. These should be evaluated at presentation in these patients.
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Chronic kidney disease (CKD) is an international public 
health problem affecting 5-10% of  the world popula-
tion.1  It is classified according to severity from stag-
es 1-5. Chronic kidney disease mineral bone disorder 
(CKD-MBD) is a systemic disorder. The broadened 
concept of  CKD-MBD, includes abnormal miner-
al metabolism (the focus of  this study), abnormalities 
in bone morphology and extra skeletal calcifications. 
These are closely inter-related and together make ma-
jor contribution to morbidity, and mortality of  patients 
with CKD.
 
The metabolic changes that occur in patients with CKD 
have a profound influence on mineral and bone metab-
olism. CKD results in altered levels of  serum phospho-
rus, calcium, vitamin D, PTH, and Fibroblast Growth 
Factor-23 (FGF-23). Beginning in CKD stage 3, the 
ability of  the kidneys to excrete a phosphorus load is 
diminished leading to raised phosphorus and PTH, and 
decreased 1,25 (OH)2D levels associated with elevat-
ed FGF-23 levels. The conversion of  25 (OH) D to 
1, 25 (OH)2D is impaired, reducing intestinal calcium 
absorption. The kidneys fail to respond adequately to 
PTH which normally promotes phosphaturia and calci-
um reabsorption; and to FGF-23 which enhances phos-
phate excretion. There is in addition, at the tissue level a 
down regulation of  vitamin D receptors and resistance 
to the action of  PTH. 
 
Bone abnormalities are found almost universally in 
patients with CKD stage 5 and in majority of  patients 
with stages 3-5.2  The biochemical abnormalities form 
the primary routine indicators in management of  
CKD-MBD, though there are limitations. Diagnosis for 
CKD-MBD using the invasive bone biopsy for bone 
turnover, mineralization, and volume; or arterial, val-
vular or coronary calcification score using gold stand-
ards such as electron beam CT, or multi-slice CT; or 
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measuring bone mineral density (BMD) by Z score of  
dual energy X ray absorptiometry (DXA), ultrasound 
or echocardiography to assess tissue calcification, are 
not necessary in routine clinical practice especially in a 
developing country as ours. Therefore, changes in se-
rum calcium, phosphorus, PTH, 25 (OH) D, and total 
alkaline phosphatase were used in this work to assess 
CKD-MBD in the study group. These changes con-
tribute to increased cardiovascular mortality in affect-
ed patients. It is also important to quantify MBD as a 
complication of  CKD even before renal replacement 
therapy (RRT) and during treatment. Interventions are 
aimed at controlling hyperphosphataemia, hyperparath-
yroidism, vitamin D deficiency among others,  and in-
clude phosphate binding, supplementation with vitamin 
D analogues, use of  calcimimetics, parathyroidectomy, 
and even kidney transplant.
 
Their pattern in pre-dialysis and especially in black CKD 
patients in developing countries is not clear. This study, 
using the biochemical methods explored the prevalence 




Eighty five adult CKD patients (in stages 3-5) and 83 
healthy control subjects presenting for the first time at 
the renal clinic and medical outpatient clinic of  the Uni-
versity of  Nigeria Teaching Hospital (UNTH), Ituku/
Ozalla, Enugu, between December 2010 and May 2011, 
were recruited consecutively for the study.
Ethical clearance was obtained from Ethics Committee 
of  UNTH, Enugu.
All subjects were physically assessed, and had serum 
PTH, 25 (OH) D, Calcium, Phosphorus, total alkaline 
phosphatase, Bicarbonate, Potassium, and Creatinine 
measured. Glomerular filtration rate (eGFR) was esti-
mated based on 4 variable MDRD formula.
PTH and 25 (OH) D were analyzed using ELISA based 
International Immuno-Diagnostics-USA; PTH EIA 
(Lot # 1386) and Vitamin D 25 (OH) EIA (Lot K2110-
100722) kits for iPTH and 25 (OH) D assays respective-
ly. The measurement of  serum 25 (OH) D is regarded 
as the best measure of  vitamin D status, because of  its 
long half-life of  approximately 3 weeks i.e. the storage 
form of  the vitamin. The active form 1, 25 (OH)2D3(-
Calcitriol) has short half-life of  4-6 hours.
Excluded were patients on dialysis, taking phosphate 
binders, calcium supplements, or vitamin D analogues; 
or having chronic liver disease, and patients with prima-
ry hyperparathyroidism or parathyroid surgery.
 
Statistical analysis
Analysis was performed using Statistical Package for 
Social Sciences (SPSS) version 20 and results were pre-
sented as means and standard deviation. Student  t test 
was used to compare patients’ variables with controls. 
X2  for trend, Spearman’s coefficient of  correlation as 
well as multiple regression analysis were used to assess 





The baseline characteristics of  the study population 
were summarized in Table 1. There were 85 patients 
and 83 controls. Majority, 63.1%  were males. The  sub-
jects were aged between 18 and 86 years. There was no 
difference between the mean age, body mass index, and 
serum calcium level of  the patients and controls. The 
weight of  the controls was significantly higher than 
the patients. The mean systolic blood pressure (SBP), 
diastolic blood pressure (DBP), serum creatinine, se-
rum potassium, phosphate, alkaline phosphatase, and 
parathyroid hormone were significantly higher in the 
patients compared to controls.  On the other hand, 
eGFR, serum bicarbonate and 25(OH) D levels were 
significantly lower in the patients compared to controls. 
The median serum PTH and 25 (OH) D levels of  the 
patients were 196.8pg/ml and 25nmol/l respectively.
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The various features of  the patients are shown in Table 
2. Chronic Glomerulonephritis, hypertension and Dia-
betes mellitus were the main causes of  chronic kidney 
Table 1: Characteristics of study population 
  
Variable                   Mean,  (Median) p  value 95% CI 
  Patients: N=85 Controls: N=83     
Age (yrs)                    48.0±15                  44.7±11.4                 NS 
Weight (kg)                65.2±10.8               73.3±10.6                 <0.001             -11.39 - - 4.83 
BMI (kg/m²)               24.5±3.4                 25.5±4.4                   NS 
SBP (mmHg)              154.1±31.7             120.2±8.8                 <0.001                26.7- 41.0 
DBP (mmHg)              92.7±19.1               76.5±7.6                   <0.001               11.7- 20.6 
SCr (µmol/l)                351.9±172.7           83.6±16.4                 <0.001               230.8-305.9 
eGFR (ml/min/1.73m²)  24.4±0.30           106.0±27.7                <0.001               -88.2- -75.1 
HCO₃ (mmol/l)            20.3±5.1                 25.9±2.0                   <0.001               -6.8- - 4.4 
K (mmol/l)                   4.9±0.84                 3.8±0.34                   <0.001               0.88 - 1.3 
Ca (mmol/l)                  2.42±0.30              2.49±0.10                  NS  
PO₄                               1.87±0.70              1.14±0.22                <0.001                0.58 - 0.90 
ALP (U/l)                     78.7±33.1               66.9±18.8                0.005                  3.58 - 20.0 
PTH (pg/ml)        318.6±276.5 (196.8)        26.6±17.2               <0.001                231.9 - 351.7 
25(OH)D(nmol/l)     28.4±11.3 (25)            93.2±31.6               <0.001                -72.0 - -57.7 
 
disease. Also, 25.9%,  50.6%, and 23.5% were in stages 
3, 4, and 5 CKD respectively. While 55.3% had acidosis 
, 41.2% had hyperkalemia.




Key: *CGN-Chronic Glomerulonephritis, HTN- hypertension, DM-diabetes mellitus, UO-obstructive 
uropathy, ADPKD-autosomal dominant polycystic kidney disease, SCN- sickle cell nephropathy, H+N-
HIV with nephropathy, S-3, 4, 5 - stages 3, 4, 5 CKD. 
Variables               n(%)         Variables           n(%)              Variables                      n(%)        
Etiology of CKD                    Clinical features                    Laboratory parameters        
*CGN                   27(31.8)      Pallor                  71(83.5)      Bicarbonate<22 
*HTN                   20(23.5)      Edema                 60(70.6)          (mmol/L)                 47(55.3) 
*DM                     17(20)         Hypertension      62(72.9)       Potassium>5      
*UO                       7(8.2)         * S-3 CKD           22(25.6)          (meq/L)                  35(41.2)           
UNKNOWN          6(7)           *S-4 CKD            43(50.6)        Calcium<2.1  
*ADPKD                3(3.5)        *S-5 CKD            20(23.5)           (mmol/L)                  5(5.9)                        
*SCN                      2(2.4)                                                           Phosphorous>1.49 
H+N                        2(2.4)                                                              (mg/dl)                    59(69.4)  
                                                                                                   ALP>95iu/L               21(24.7) 
                                                                                                   PTH>65                       72(84.7)  
                                                                                                   Vit. D deficiency         53(62.4) 
                                                                                                   Vit. D insufficiency     32(37.6 
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For the markers of  CKD-MBD, all patients had low 
levels of  25 (OH) D, 62.4% had vitamin D deficiency, 
while 37.6% had  insufficient vitamin D.  84.7% of  the 
patients had hyperparathyroidism, 69.4%  hyperphos-
phataemia, 24.7%  high levels of  alkaline phosphatase, 
while only 5.9% had hypocalcaemia. No patient had 
combination  of  hypocalcaemia, hyperphosphataemia, 
high alkaline phosphatase, low vitamin D, and hyper-
parathyroidism. Only 3 patients (3.5%) had combined 
hypocalcaemia, hyperphosphataemia, low vitamin D 
levels, and hyperparathyroidism, while 15.3% had com-
bined high alkaline phosphatase levels with high phos-
phorus, high PTH, and low vitamin D levels. 63.5% had 
combined hyperphosphataemia, hyperparathyroidism 
and low vitamin D levels and even higher numbers, 
84.7% had hyperparathyroidism and low 25 (OH) D 
levels.
There was a progressive increase observed in serum po-
tassium, phosphorus, and PTH from stage 3 to 5 CKD, 
while the converse was noted for serum bicarbonate 
and 25 (OH)D( table 2).
 
Table 3 showed the correlation values of  serum PTH 
and serum phosphorous levels with various variables 
in the patients. Serum PTH levels correlated positive-
ly with diastolic BP, serum potassium and phosphorus, 
but negatively with eGFR, and serum bicarbonate lev-
els. Upon correcting for eGFR (β =-0.318, p =0.011), 
and diastolic BP (β =0.252, p =0.012) with multiple re-
gression analysis, the observed correlation disappeared. 
Serum phosphorus correlated negatively with eGFR 
and serum bicarbonate but positively with serum potas-
sium. However, on multiple regression, only eGFR (β 
=-0.449, p =0.0001), and serum Potassium (β =0.222, p 
=0.019) demonstrated significant correlation. 25(OH) 
D did not correlate with other parameters.
Table 3: Correlations of serum PTH and serum phosphorous with various variables. 
  
                                                        Correlations for PTH 
Variable                                            Coefficients (r)                                      p value 
  
DBP                                                  0.289                                                     0.007 
K                                                      0.281                                                     0.009 
PO₄                                                   0.386                                                     0.0001 
eGFR                                                -0.533                                                    0.0001 
HCO₃                                                -0.293                                                    0.007 
  
                                                        Correlations for PO₄ 
  
K                                                      0.399                                                       0.019 
eGFR                                                 -0.643                                                     0.0001 
HCO₃                                                 -0.468                                                     0.0001 
 
Table 4 showed the prevalence of  various vitamin D 
abnormalities in the different stages of  CKD. Vitamin 
D deficiency worsened as CKD stage increased. How-
ever, prevalence of  vitamin D insufficiency (relative 
higher Vitamin D levels) appeared to fall with worsen-
ing renal function. The changing pattern of  vitamin D 
insufficiency and deficiency with increasing CKD stage 
was assessed using X² test for trend. 
 
Table 4: Prevalence of 25 (OH) D levels in various CKD stages. 
  
 25 (OH) D levels           CKD 3.(%)    CKD4.(%)      CKD5.(%)        Total    
>75nmol/l(Normal)             0                           0                 0                      0 
30-75 ,, (Insufficient)        54.5                      37.2            20                  37.6 
 <30   ,, (deficient)            45.5                       62.8           80                   62.4 
Total                                 100                       100             100                  100 
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This showed a strong evidence that the odds of  vita- min D deficiency increased significantly with increasing 
CKD stage (table 5).
Table 5: X² test for trend of 25 (OH) D in various CKD stages. 
  
25(OH) D status      Stage 3      Stage 4          Stage 5         Total           X² for trend        p 
value 
Deficiency          10(45.5%)     27(62.8%)     16(80%)       53(62.4%) 
Insufficiency       12(54.5%)     16(37.2%)     4(20%)         32(37.6%) 




The individuals studied were all Ibo Nigerians, of  the 
black race: an adverse risk factor for kidney diseases.3 
They were mostly middle aged as against the geriatric 
CKD patients seen in developed countries. Studies in 
the past in Nigeria, and in most sub- Saharan African 
countries, showed that kidney diseases occur in relative-
ly younger age group.4,5,6 Most of  the patients had pallor 
(83.5%) even at stage 3 disease, most also had periph-
eral edema (70.6%) and half  of  them had other symp-
toms of  uremia at first presentation. Haemoglobin esti-
mation would have given a more objective estimate of  
those that are pale. However, this was not included in 
our protocol as it has no direct bearing on the objec-
tives of  the study. Majority of  our patients present late, 
(50.6%) presented at stage 4 in this study.  Late pres-
entations/ referrals contributed to poor outcomes in 
our CKD patients. This finding is similar to other stud-
ies that noted late presentation and severe illness at first 
presentation.5,7,8,9 The predominant causes of  ESRD 
in Africa are essentially CGN and hypertension, with 
both sharing the lead in most study series.6 This study 
found CGN the predominant cause of  CKD. However, 
a rise of  the percentage contribution of  diabetes has 
been noted in various centers, consistent with urbaniza-
tion and improvement in the living standards in African 
countries.10 Diabetes was the 3rd most common cause 
of  CKD in this study, accounting for 20% of  cases.
Markers of  CKD-MBD
Studies have shown that decreases in calcitriol levels 
occurred in patients with early CKD and preceded in-
creases in serum PTH levels.11 These are in agreement 
with this study in which none of  the patients had suffi-
ciency of  25 (OH) D (from FGF-23 inhibition), while 
about 15% of  them had normal levels of  PTH.
Though most of  these patients (76%) were not in  end 
stage renal disease, there was still a high prevalence of  
these markers of  CKD-MBD. This may explain the 
high mortality rates even in earlier stages of  CKD.  This 
study showed low levels of  vitamin D, with high rates 
of  hyperparathyroidism and hyperphosphataemia.
 
In SEEK study12, where pre-dialysis patients were sim-
ilarly studied, it was found that blacks had significantly 
lower levels of  25(OH) D but   higher levels of  calcium, 
phosphorus and PTH. This high secondary hyperpar-
athyroidism (SHPT) and 25(OH) D deficiency occurs 
early in the course  of  CKD, irrespective of  age, gen-
der, diabetes mellitus, eGFR, calcium and phosphorus. 
Some studies have suggested that this high prevalence 
might be due to blacks having reduced calcium sensing 
capacity,13 or due to greater skeletal resistance to PTH 
among blacks.14
 
The patients and controls had normal mean serum cal-
cium levels which were not significantly different be-
tween them. Again, in the CHOICE study,15 serum cal-
cium level at the commencement of  dialysis was 2.34 
mmol/L, similar to values in our study. Llach et al,16 
also found from their work that serum calcium, phos-
phorus, and ALP are usually normal, until late in the 
course of  CKD. Our study like the one by Gutierrez et 
al12 has shown that raised PTH and phosphorus levels, 
do occur with normal calcium and low vitamin D levels, 
especially among blacks. In-fact calcium is said to be 
frequently but not consistently abnormal with reduced 
GFR.17 Since the results in our study are cross sectional, 
causal relationships between dependent variables (kid-
ney function) and independent variables (PTH, Vitamin 
D metabolites, calcium and phosphorous) cannot be 
defined. No longitudinal data has been reported here, 
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thus relationships between the variables and different 
eGFR levels may change over time in different individ-
uals.   
 
There was a 69.4% hyperphosphataemia in this study. 
This high prevalence is similar to those found in Benin, 
Nigeria by Onyemekeihia et al18 (79%) and Sanusi et al19 
at Ife, Nigeria (60%). The high prevalence of  hyper-
phosphataemia occurs despite the fact that Africans are 
likely to have lower daily intake of  dairy products and 
other sources of  calcium and phosphorus.12 This might 
be due to renal resistance to the phosphaturic stimulus 
of  raised PTH seen in blacks.17
 
There is currently a phosphate-centric paradigm for the 
pathophysiology and therapy of  CKD. In our environ-
ment, serum phosphorus is routinely assayed in patients. 
There is, the tendency to treat hyperphosphataemia 
with available calcium containing phosphate binders 
inaddition to vitamin D analogues. Also patients are 
dialyzed with high calcium containing dialysate. With-
out concomitant assays of  serum PTH, vitamin D, and 
FGF-23, this practice no longer enjoys a favorable re-
view, and predisposes patients to Adynamic bone dis-
ease (ABD) which worsens vascular calcification type 
of  MBD as noted, in the work by Sanusi et al.18 Also, 
calcium in these compounds has a stimulatory effect 
on the secretion of  FGF-23 which further sustains the 
MBD. This however is not the case with Sevelamer or 
Lanthanum carbonate.20
 
Though ALP levels, were significantly higher in pa-
tients than controls, absolutely high levels of  total ALP 
(>95U/L) were insignificant in both groups and showed 
that this affordable assay is not a valid surrogate marker 
for CKD-MBD in pre-dialysis patients. The bone frac-
tion (bALP), however might be. Raised ALP has been 
shown to have a linear and incremental association with 
both all cause and cardiovascular disease mortality21 be-
cause it reduces the pyrophosphate/phosphate ratio. 
Pyrophosphate is an inhibitor of  vascular calcification.
 
All patients in this study had low 25(OH) D levels. The 
study showed that majority of  the patients (62.4%) had 
25 (OH) D deficiency, worse in stage 5 than 3, and the 
remaining 37.6% had insufficiency, more in stage 3 than 
5. The progressive deficiency in the stages was found 
to be significant by X2 for trend. The Gutierrez et al12 
study found low levels of  25(OH) D as well, in Blacks. 
Other studies done in USA22,23 and UK24 showed similar 
findings. Wolf  et al23 found 78% of  patients they stud-
ied, had low 25(OH) D i.e. <75nmo/L, with blacks be-
ing more deficient than whites. Gonzalez et al,22 found 
that 86% of  43 CKD patients they studied had inade-
quate 25(OH) vitamin D. Kosmadakis et al,24 studied 
stages 3 and 4 CKD patients, found 25(OH) D insuf-
ficiency with values not much different in the 2 stages 
(39.8±24 versus 38.3±22.3nmol/L). This feature was 
similar to our findings. The finding of  low 25 (OH) D 
in our  study is significant considering the increased all-
cause mortality noted in patients with deficiency as was 
documented by Mehrota et al.25 They studied 3011 pre-
dialysis patients, found that those with 25(OH) D levels 
<37.5nmol/L had increased risk for all-cause mortality, 
compared to those with vitamin D sufficiency.  
 
Levin et al,11 found a high SHPT prevalence of  56% 
in mainly stages 3 and 4 pre-dialysis patients. The 
mean PTH levels were noted to be 71.7±59.08, and 
185.5±159.88pg/ml respectively. They did not study 
stage 5 disease patients. The higher prevalence and 
higher values in our study could be explained by vari-
ous factors. The patients in this study were younger and 
purely blacks and both factors have been documented 
as causes of  high SHPT.26 Furthermore, our study also 
included stage 5 CKD patients.  PTH level > 300pg/ml 
is associated with Blacks, long duration of  ESRD and 
varies inversely with age.27 Similar to this index study, 
Levin el al11 found no correlation between hyperpar-
athyroidism and serum calcium, and ALP especially in 
stage 3 disease. This underscores the need to assay PTH 
levels for diagnosis of  MBD early in CKD as calcium, 
ALP, and phosphorus may be normal even with elevat-
ed PTH.
 
It was instructive that as expected, both hyperparath-
yroidism and hyperphosphataemia correlated inversely 
with eGFR, even in multiple regression analysis. How-
ever, that vitamin D levels did not correlate with eGFR 
could be explained by its inhibition caused early by in-
creased FGF-23 in the course of  MBD. Unfortunately 
FGF-23 was not assayed in the study.
 
Conclusion
The findings of  this study suggest that MBD as a com-
plication is common in our CKD patients. Raised PTH, 
low 25(OH) D, and raised phosphorus levels were the 
most prevalent markers, even in this population of  
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pre-dialysis patients. Total alkaline phosphatase was 
not found to be a good surrogate marker for CKD-
MBD in our predialysis patient population. It did not 
correlate with early markers - serum PTH and vitamin 
D. This cheap MBD marker may therefore not be ide-
al in pre-dialysis CKD patients.  Majority of  our pa-
tients presented, or were referred late. Clinical features 
of  MBD in CKD were poor guides to the presence of  
MBD in our pre-dialysis patients. It therefore may not 
be proper for practitioners to wait for symptoms and 
signs to manifest.
Limitations of  the study
Due to the cross-sectional nature of  this study, patients 
were assessed only at presentation. There is a chance of  
changes in CKD stages estimation on further patient 
follow up. There are also diurnal variations in the me-
tabolites assayed, some variations occur with meals, and 
different coefficients of  variation of  assays exist.  Bone 
fraction (bALP) ALP and FGF-23 levels could not be 
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